Remove topic global
article thumbnail

With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy

Fierce Pharma

Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million.

123
123
article thumbnail

Biopharma’s rapid transition to omnichannel marketing

pharmaphorum

In today’s episode, sponsored by Veeva, we’ll hear a roundtable discussion on this fascinating topic featuring Victoria Serra Gittermann, European customer experience lead at Veeva Systems and Sebastian Noel, Veeva’s director of multichannel strategy – moderating a discussion with two executives with first-hand experience leading this change: Andy (..)

121
121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Improving patient experience doesn't come at cost of site burden Mural Health says

Outsourcing Pharma

Mural Health is on a mission to make it as easy as possible for people to take part in clinical trials, the company will be heading to DIA Global in Boston where they hope to glean a meaningful understanding of the current landscape and hot topics.

81
article thumbnail

HP&M’s Larry Houck A Panelist at FDLI’s Cannabis Regulation Conference

The FDA Law Blog

Hyman, Phelps & McNamara Director Larry Houck will participate as a panelist focusing on this timely topic at the Food and Drug Law Institute’s (“FDLI’s”) Legal and Practical Issues in Cannabis Regulation Conference next month. The conference, held in Washington, D.C., April 4th and 5th, is an in-person and virtual event.

article thumbnail

Opinion: What the recent failures of Mindstrong and Pear tell us about the future of digital mental health

STAT

Over the past five years, digital mental health has risen from a niche topic to a global health priority. Patients, researchers, regulators, and investors alike are thrilled by the potential of ubiquitous mobile technology like smartphones to help diagnose problems, monitor health, and even deliver evidence-based therapies.

FDA 100
article thumbnail

Interview: Andrew MacGarvey COO of Phastar on opportunities for big analytical data

Outsourcing Pharma

We caught up with him earlier in the summer at DIA Global in Boston to discuss the companyâs origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning among many other topics. Andrew MacGarvey is chief operating officer (COO) of Phastar.

52
article thumbnail

Regulatory, Compliance and Quality Challenges, Learnings, and Future Opportunities

ISPE

The Regulatory, Compliance, and Quality sessions, promise to be a comprehensive exploration of the vital topics shaping the pharmaceutical landscape. One of the industry's challenges is navigating the complex global regulatory frameworks that govern drug development, manufacturing, and distribution.

FDA 98